Sorafenib is a multikinase inhibitor targeting PDGF-A/B, VEGFR1-3, c-kit, RET, and various proteins of the kinase cascade, Ras, C-Raf, B-Raf, ERK, FLT-3, JAK/STAT as well as MAPK, contributing to its antitumor effect by decreasing tumor cell proliferation, inducing apoptosis, and suppressing angiogenesis [14,348]. This evidence concerns the gene FLT3 and neoplasm.